Skip to main content

Advertisement

Table 1 Demographic and descriptive characteristics of study participants

From: Lipid levels in HIV-positive men receiving anti-retroviral therapy are not associated with copy number variation of reverse cholesterol transport pathway genes

  HDL ≤ 40 mg/dL HDL = 40–60 mg/dL
LDL ≤100 mg/dL 100-130 mg/dL 130–160 mg/dL ≥160 mg/dL LDL Not Measured ≤100 mg/dL 100–130 mg/dL 130–160 mg/dL
HIV Status HIV− HIV+ HIV− HIV+ HIV− HIV+ HIV− HIV+ HIV− HIV+ HIV− HIV+ HIV− HIV+ HIV− HIV+
n 17 46 12 27 19 7 3 4 1 7 23 15 19 11 17 12
Median
Age (years) 51 48.5 53 48 45 55 40 46.5 56 46 48 46 50 50 48 46
BMI 31.6 25.2 27.8 25.2 28 23.9 27.5 30.2 30.6 23.4 27.1 24.7 26.4 24.8 26.9 24.2
HDL (mg/dL) 34 29.1 34.5 31 36 34 37 35.9 28 28.6 50 48.2 50 48 51 46.7
LDL (mg/dL) 78 78.5 121 115 145 142 172 175 130 76 86 112 110 145 140
TCHOL (mg/dL) 153 143 189 188 213 214 241 253 181 182 146 151 185 187 215 225
TRIG (mg/dL) 203 197 205 225 152 156 132 148 114 434 81 102 110 108 101 178
# on therapy
No therapy 12 9 2 1 2 3 2
Mono-therapy   1
Combination 5 1  
Potent ART 29 17 5 3 5 12 10 10
Therapy adherence
100 % 10 7 3 2 3 4 5
95–99 % 19 8 2 1 5 8 6 4
<75 % 3 2   1 1
NA 14 10 2 1 2 3 1 2
BGA
AEA 4 3 5 4 1 6 3 7 2 1 2
AsEA 1 2 1 2 1
EA 15 39 8 22 15 7 3 3 1 6 16 12 12 9 14 9
NA 1 1 1 1
Group total 17 46 12 27 19 7 3 4 1 7 23 15 19 11 17 12
  1. BMI, body mass index; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TCHOL, total cholesterol; TRIG, triglycerides; monotherapy, single nucleoside reverse transcriptase inhibitor; Combination, two or more nucleoside reverse transcriptase inhibitors; potent ART, two or more nucleoside reverse transcriptase inhibitors with a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor; BGA, biogeographical ancestry; AEA, African/European ancestry; EA, European ancestry; AsEA, Asian European ancestry
  HDL = 40–60 mg/dL HDL ≥ 60 mg/dL   
LDL ≥160 mg/dL LDL not measured ≤100 mg/dL 100–130 mg/dL 130–160 mg/dL ≥160 mg/dL LDL not measured   
HIV Status HIV− HIV+ HIV− HIV+ HIV− HIV+ HIV− HIV+ HIV− HIV+ HIV− HIV+ HIV− HIV+   
n 13 4 1 1 8 15 8 7 2 6 3 6 1 4   
Median   
Age (years) 50 49 22 52 45 42 46.5 52 53.5 47 59 47 31 45.5   
BMI 27.8 26.2 20.7 27.4 25.7 22.9 24.8 23.9 27.3 22.6 26.6 22.5 22.7 24.7   
HDL (mg/dL) 51 45 54.6 40.6 73.5 76.1 63.3 75.9 64.3 82.4 62.5 68.5 60 71.8   
LDL (mg/dL) 165 175 92.5 80 119 111 138 144 167 167 130   
TCHOL (mg/dL) 245 251 163 176 181 181 203 205 223 249 247 259 224 236   
TRIG (mg/dL) 134 122 86 103 104 94 101 102 105 98 168 525   
# on therapy   
No therapy 4 1 2 2   
Mono-therapy   
Combination 2   
Potent ART 4 1 9 6 4 4 4   
Therapy adherence   
100 % 2 5 1 3 2   
95–99 % 2 3 4 2   2   
<75 % 1 3 1 2 1   
NA 4 1 2 2   
BGA   
AEA 3 1 1 11 3 4 1   
AsEA 1 3 1   
EA 10 4 1 6 1 5 7 2 2 3 5 1 2   
NA 1   
Group total 13 4 1 1 8 15 8 7 2 6 3 6 1 4   
  1. BMI, body mass index; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TCHOL, total cholesterol; TRIG, triglycerides; monotherapy, single nucleoside reverse transcriptase inhibitor; Combination, two or more nucleoside reverse transcriptase inhibitors; potent ART, two or more nucleoside reverse transcriptase inhibitors with a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor; BGA, biogeographical ancestry; AEA, African/European ancestry; EA, European ancestry; AsEA, Asian European ancestry